Transactions – Page 2

Divestiture of Horizon’s Research Models Business to Envigo

Horizon Discovery Divests Animal Models Business to Envigo * Animal model operations to be transferred to Envigo ownership * Divestment in line with Horizon’s corporate strategy to focus on its core markets * Envigo, a leading global research model supplier, enters the gene-edited research model field with the addition of Horizon’s business * Horizon and Envigo to collaborate on providing CRISPR screening services CAMBRIDGE, England -- November 8, 2019 Horizon Discovery Group plc (LSE: HZD) ("Horizon", “the Company” or “the Group”), a global leader in the application of gene …

Divestiture of Natera’s Evercord Cord Blood Business to CBR

LOS ANGELES, Sept. 13, 2019 /PRNewswire/ -- CBR (Cord Blood Registry), the world's largest newborn stem cell collection and storage company, today announced the asset acquisition of Natera, Inc.'s (NASDAQ: NTRA) Evercord™ newborn stem cell business. The mutually beneficial move brings together two of the industry's most respected newborn stem cell storage companies. "As a pillar of the California Cryobank Life Sciences (CCLS) organization, CBR is built on scientific excellence, leadership, and best-in-class services," said Richard Jennings, California Cryobank Life Sciences, …

Sale of HealthGrid to AllScripts Healthcare Solutions

HealthGrid is a leader in the rapidly evolving healthcare patient engagement sector. Industry analyst KLAS defines patient engagement as “the process of motivating and enabling patients to participate in their own care with the expectation that, over time, outcomes will improve and costs will be reduced”. HealthGrid’s intelligent patient engagement technology platform enables providers to stay connected with their patients’ pre-care, point of care and post care, keeping them engaged, informed and supported throughout the healthcare continuum. Please refer to the Company’s website for …

Sale of Dynex Technologies to Telegraph Hill Partners

Dynex Technologies, headquartered in Chantilly, Virginia, with offices in Hong Kong, Germany and the U.K., pioneered microplate technology more than 60 years ago, and has since delivered a series of cutting edge, best-in-class ELISA processing systems, including the 4-plate DSX, 2-plate DS2 and Agility high throughput systems. Dynex designs each of its products to meet the rigorous demands of the clinical laboratory. Convergence was engaged by Dynex and its financial sponsors to pursue a strategic alternatives for Dynex including a sale of the Company. Convergence worked with management to …

Sale of Magellan Diagnostics to Meridian Bioscience

Magellan Diagnostics, Inc, headquartered in Billerica, MA pioneered the engineering, development and manufacturing of FDA-cleared products for the testing of blood to diagnose lead poisoning in children and adults. Convergence was engaged by Magellan and its financial sponsors, to pursue a sale of the Company. Convergence worked actively with Chairman Peter Glick and CEO Amy Winslow to craft a strategic marketing plan for the company that leveraged Magellan's historical performance as a market leader in Lead exposure testing while valuing the opportunity created by Magellan's next …

Sale of Lumora, Inc. to ERBA Diagnostics Mannheim

Lumora is a successful provider of state-of-the-art molecular diagnostic products into both the clinical and non-clinical or industrial markets. Lumora's technology is easy-to-deploy and use making it ideal to be deployed in fields as diverse as food safety testing, and medical diagnostics. The Company currently has products that are actively commercial has a number of leading development and commercialization partners include international biotechnology, clinical diagnostic and industrial microbiology companies Convergence had been engaged by Lumora’s Board of Directors to help the Company …